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 In 2016, the CDC reported an estimated 20.4% (50 million) of 
U.S. adults had chronic pain [1]
 The American Academy of Sleep Medicine estimates 
around 30% of U.S. adults have symptoms of insomnia [2]
 And 10% of U.S. adults have severe insomnia with daytime 
consequences [2]
 Anxiety is estimated to affect 40 million U.S. adults 
according to the Anxiety and Depression Association of 
America, making anxiety disorders the most common 
mental illness in the U.S. [3]
 In a 2017-2018 survey of CBD users, 62% identified using CBD 
to treat a medical condition [6]
 The top three conditions listed were pain, anxiety, and 
depression [6]
 The same survey found the odds of CBD use to treat a 
medical condition were 1.44 times greater among non-
regular users of Cannabis compared to regular users [6]
 36% of respondents reported CBD as specific or sole therapy 
for their identified medical condition [6]
Description 
of Need (2B)
 The demand for CBD products in increasing among 
American consumers [5]
 Many companies producing and selling CBD products 
have been making unsubstantiated drug claims about 
their products – including that CBD can treat, or cure, 
cancer [5]
 Due to a lack of FDA oversight and enforcement of CBD 
products, an estimated 70% of CBD products offered 
online could be mislabeled (with both under or over-
labeling of the CBD and THC content) [5]
 The lack of meaningful regulation of cannabidiol 
products leaves consumers at an increased risk of using 
products with unspecified concentrations of CBD and 
thus unknown therapeutic value [5]
 There is a lack of general knowledge and understanding 
among consumers as to the scientifically substantiated 
evidence behind CBD therapy [5]
Cost 
Considerations
 Patients suffering from an anxiety disorder are 3-5 
times more likely to go to the doctor and 6 times 
more likely to be hospitalized for psychiatric 
disorders [3]
 A 2016 Fiscal Report from the Vermont Agency of 
Human Services Department of Mental Health 
identified ‘anxiety and other nonpsychotic 
disorders’ as the most common ICD-10 mental 
health diagnosis code among outpatient services 
(52%) and community rehabilitation programs 
(29%) [13]
 In 2017, insufficient sleep among working adults in 
the U.S. was estimated to generate an annual 
economic loss between $280 billion and $411 billion
[11]
 This loss will range from $299 to $433 billion by 2020 [11]
 And $318 to $456 billion by 2030 [11]
 By 2020, it is projected that retail sales of CBD 
products will have increased to $1.9 billion [5]
Community Perspective and Support
 “I had other friends with chronic pain that tried CBD and it really worked for 
them, so I figured I would try out what they had found helpful. I’m not sure 
it’s working for me yet, but there’s so many options available that I’m 
interested in trying something else. Most of my information has come from 
my own research, but I still have a lot of questions about how it works and 
why there are different formulations. I really like that it doesn’t give you the 
‘high’ of THC though, so I’m hopeful I can find what is right for me.”                                        
– Chittenden County resident and CBD user
 “Patients often ask what CBD can be used for, what dose to take, if it 
interacts with their other medications, if it could show up on a drug test, 
and if I can write them a prescription…patients that are already on the VT 
Medical Marijuana Registry can get access and expertise through 
dispensaries…but I don’t really have any great resources and wish I was 




 Created an educational trifold leaflet for patients to:
1. Identify the current medical understanding of CBD 
2. Address its proven therapeutic potential to-date
3. Pinpoint what to look for when purchasing CBD 
products
4. Recommend dosing for specific medical conditions
5. Correct common myths about CBD
6. List local and online resources for more information
7. Encourage conversations with health care providers
 Created a “dot phrase” (CBDPTINFO) on EPIC with 
similar information and additional resources for patients
 Shared phrase with physicians at UVMC FMH to include 
in patient’s “after visit summary”
Results/Responses
 Handout was offered for distribution at
the UVMMC Family Medicine Hinesburg 
office, as well as to individual providers at 
that location
 “dot phrase” was shared with UVMMC 
FMH providers
 Response to handout and “dot phrase” 
was positive among providers
 No formal response data was received
 Providers appreciated the compiled 




 Due to time constraints, the effectiveness 
of this intervention was not assessed
 Future assessment could involve:
 A survey to patients at FMH regarding:
 Ability to understand handout
 If handout provided new information
 Whether handout resulted in change in 
CBD habits
 If they felt more confident finding 
information on CBD and purchasing CBD 
products
 If they were more likely to discuss CBD with 
their healthcare provider(s)
 A survey to providers at FMH regarding:
 If patients questions/understanding of CBD 
changed following handout distribution
 How frequently they were using the EPIC 
“dot phrase”
Limitations
 Limited follow-up to evaluate handout 
utilization and response
 Effectiveness is dependent on 
adequate distribution to patients
 Effectiveness is dependent on patient 
reading handout or after visit summary 
 Effectiveness is dependent on English 
language literacy
 Handout and “dot phrase” limited to 
introductory information on CBD
 Impossible to know whether patients 
would have found provided 
information independently
Recommended Future Interventions 
Update and expand handouts in 1 year - due to high turnover rate of 
evidenced- base published studies on CBD
Distribute handout to other family medicine offices and providers in 
Vermont
Distribute handout to other providers not associated with family medicine
Compile data regarding CBD use among Vermont patients
Connect more patients and providers with Paul Jerard at the Vermont 
Cannabinoid Clinic and Ada Puches at the Champlain Valley Dispensaries
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